TD Asset Management Inc Increases Holdings in Cytokinetics, Incorporated $CYTK

TD Asset Management Inc grew its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) by 23.4% during the third quarter, HoldingsChannel reports. The fund owned 671,780 shares of the biopharmaceutical company’s stock after purchasing an additional 127,488 shares during the period. TD Asset Management Inc’s holdings in Cytokinetics were worth $36,921,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dana Investment Advisors Inc. raised its holdings in Cytokinetics by 4.9% during the third quarter. Dana Investment Advisors Inc. now owns 17,413 shares of the biopharmaceutical company’s stock worth $957,000 after purchasing an additional 811 shares in the last quarter. Intrust Bank NA purchased a new position in shares of Cytokinetics in the 3rd quarter valued at $250,000. Monaco Asset Management SAM raised its stake in Cytokinetics by 182.4% during the 3rd quarter. Monaco Asset Management SAM now owns 120,000 shares of the biopharmaceutical company’s stock worth $6,595,000 after acquiring an additional 77,500 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in Cytokinetics by 280.7% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 149,957 shares of the biopharmaceutical company’s stock worth $8,242,000 after acquiring an additional 110,568 shares in the last quarter. Finally, Fifth Third Bancorp lifted its position in Cytokinetics by 32.3% in the third quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 262 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. B. Riley Financial lifted their target price on Cytokinetics from $90.00 to $108.00 and gave the stock a “buy” rating in a research report on Wednesday, January 21st. Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research note on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a research report on Wednesday, January 21st. UBS Group reaffirmed a “neutral” rating and issued a $61.00 target price on shares of Cytokinetics in a report on Monday, December 1st. Finally, Needham & Company LLC increased their price target on shares of Cytokinetics from $84.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday. Seventeen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $88.83.

Insider Activity at Cytokinetics

In other news, EVP Andrew Callos sold 15,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $61.93, for a total transaction of $928,950.00. Following the completion of the transaction, the executive vice president directly owned 50,440 shares of the company’s stock, valued at approximately $3,123,749.20. This represents a 22.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Wendell Wierenga sold 20,000 shares of Cytokinetics stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the completion of the sale, the director owned 32,444 shares in the company, valued at approximately $2,145,846.16. This trade represents a 38.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 151,385 shares of company stock worth $9,817,158 over the last 90 days. Company insiders own 2.70% of the company’s stock.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Leerink Partners raised its price target from $83 to $84 and kept an “outperform” rating, signaling continued institutional confidence in the stock’s upside potential. Leerink Partners raise
• Positive Sentiment: HC Wainwright continues to rate CYTK a “Buy” with a $136 price target — an aggressive upside relative to current levels, which supports longer-term investor optimism despite near-term volatility. HC Wainwright coverage
• Positive Sentiment: Investor commentary pieces remain bullish (e.g., recent “Why Cytokinetics is a Buy” article), which can help sustain retail interest and buying momentum over time. Why CYTK is a buy
• Neutral Sentiment: Reported short-interest data for late February shows anomalous/zero values (0 shares, 0.0 days-to-cover) — likely a data/reporting issue, so it provides no clear signal about directional pressure.
• Negative Sentiment: Shares moved down after the company’s recent quarterly report missed EPS expectations and triggered a negative market reaction; coverage noted a sharp intraday decline following the results. Weak earnings coverage
• Negative Sentiment: HC Wainwright cut EPS forecasts across FY2026–FY2028 and several quarters (Q1–Q4 2026), materially lowering near‑term profitability expectations even as it held a buy rating — a factor pressuring valuation multiples today. HC Wainwright estimate changes

Cytokinetics Price Performance

NASDAQ:CYTK opened at $62.22 on Friday. The firm’s fifty day moving average price is $64.20 and its 200 day moving average price is $58.58. Cytokinetics, Incorporated has a 1-year low of $29.31 and a 1-year high of $70.98. The firm has a market cap of $7.61 billion, a price-to-earnings ratio of -9.53 and a beta of 0.54.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. The business’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.26) EPS. As a group, analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.